Biohaven (NYSE:BHVN – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.
A number of other brokerages have also recently issued reports on BHVN. TD Cowen restated a “buy” rating on shares of Biohaven in a research note on Wednesday, August 26th. HC Wainwright reaffirmed a “neutral” rating and issued a $10.00 target price on shares of Biohaven in a research report on Thursday, September 10th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Biohaven in a research report on Friday, June 26th. Morgan Stanley lifted their price objective on Biohaven from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Finally, Bank of America reissued an “underperform” rating and set a $11.00 price objective (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.25.
Read Our Latest Stock Analysis on Biohaven
Biohaven Stock Down 5.5%
Shares of NYSE:BHVN opened at $13.89 on Friday. The stock has a 50-day simple moving average of $13.51 and a 200-day simple moving average of $12.70. The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73. Biohaven has a 1 year low of $7.48 and a 1 year high of $18.57. The stock has a market capitalization of $2.10 billion, a P/E ratio of -2.99 and a beta of 1.35.
Biohaven (NYSE:BHVN – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). Equities analysts forecast that Biohaven will post -3.33 earnings per share for the current year.
Institutional Trading of Biohaven
Several hedge funds and other institutional investors have recently bought and sold shares of BHVN. Sterling Capital Management LLC grew its stake in Biohaven by 847.5% in the third quarter. Sterling Capital Management LLC now owns 4,444 shares of the company’s stock worth $59,000 after purchasing an additional 3,975 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new position in shares of Biohaven during the 2nd quarter valued at approximately $60,000. Essential Partners LLC lifted its position in shares of Biohaven by 31.7% during the 1st quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock valued at $76,000 after buying an additional 2,169 shares in the last quarter. IFP Advisors Inc raised its position in shares of Biohaven by 43.3% in the second quarter. IFP Advisors Inc now owns 6,011 shares of the company’s stock valued at $89,000 after buying an additional 1,816 shares during the last quarter. Finally, 4WEALTH Advisors Inc. acquired a new position in Biohaven during the first quarter worth $116,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.
More Biohaven News
Here are the key news stories impacting Biohaven this week:
- Positive Sentiment: FDA review removes a key regulatory hurdle. The FDA accepted Biohaven’s resubmitted application, meaning the agency will conduct a formal review of Vyglxia. A regulatory decision is expected in the first quarter of 2027. Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
- Positive Sentiment: Investors are reassessing the drug’s commercial potential. Coverage highlighted the possibility that approval could give Biohaven a significant new growth opportunity in a rare neurological disease, helping explain the stock’s unusually large advance and some analyst price-target increases. Biohaven Soars 25% on FDA Drug Review, Price Target Upgrade
- Positive Sentiment: Trading activity reinforced the bullish move. Investors purchased 6,072 BHVN call options, approximately 155% above typical daily call volume, signaling heightened speculative interest in further upside. Why Biohaven catapulted 30%-plus and why it might not be done sprinting
- Neutral Sentiment: The FDA has accepted the application for review—not approved Vyglxia. The upcoming review creates a major catalyst, but the outcome remains uncertain and the company still faces the time and expense of completing the regulatory process. Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission
- Negative Sentiment: Sharp gains increase volatility and profit-taking risk. The stock’s rally appears driven largely by a single regulatory event and options activity, while Biohaven remains an unprofitable biotech. Any negative FDA feedback, delay, or questions about Vyglxia’s efficacy or market opportunity could reverse the move.
Biohaven Company Profile
Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.
Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.
See Also
- Five stocks we like better than Biohaven
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.
